Neuro-Hitech Pharmaceuticals has signed a development agreement with Xel Herbaceuticals to develop a transdermal patch to treat Alzheimer's disease. The therapeutic agent is Huperzine A, a molecule currently undergoing Phase II clinical testing as an orally administered treatment for mild-to-moderate Alzheimer's disease.
Neuro-Hitech has completed two Phase I clinical studies on healthy elderly subjects for orally administered Huperzine A. The Phase I study results showed no medication doses missed because of adverse events related to treatment, no evidence of GI toxicity, and no adverse effect on vital signs, exams, labs, or ECG. In addition 30- and 90-day animal toxicity studies have been completed on Huperzine A in conjunction with the National Institute of Aging, a division of the NIH.